摘要
目的:探讨尿激酶型纤溶蛋白酶激活剂(uPA)表达在乳腺浸润型导管癌中的表达及其与临床病理特征的关系。方法:采用免疫组织化学技术研究我院1990～2001年233例浸润型导管癌标本uPA、雌激素受体(ER)、孕激素受体(PR)及C-erbB-2的表达,探讨uPA表达与浸润型导管癌临床病理特征及与ER、PR、C-erbB-2表达的关系。结果:uPA表达与浸润型导管癌腋窝淋巴结转移、临床分期、C-erbB-2表达呈正相关(P<0.05);与ER、PR表达呈负相关(P<0.05)。uPA表达与病人年龄、肿瘤大小、组织学分级无显著相关。结论:uPA高表达对评价乳腺癌恶性程度和预测转移有重要作用,可作为评价乳腺癌预后的辅助指标,但需要进一步的随访研究。
Objective To evaluate the expression of urokinase-type plasminogen activator (uPA) in invasive ductal carcinoma of breast and its clinical significance. Methods Two hundred and thirty-three patients with invasive ductal carcinoma of the breast, diagnosed in our hospital over 1990-2001, were included in this study. The uPA expression was evaluated by immunohistochemistry. The relationship between uPA expression and clinicopathological features of invasive ductal carcinoma such as tumor grading, tumor size, expression of estrogen receptor (ER),progestogen receptor (PR) and C-erbB-2, axillary lymph nodes involvement and clinical staging was also investigated accordingly. Results The expression of uPA was significantly correlated with clinical staging, axillary lymph nodes involvement and the C-erbB-2 expression status of invasive ductal carcinoma of the breast; The expression of ER and PR was negatively correlated with the uPA expression; No significant correlation was found between the uPA expression and tumor size and histological grading. Conclusions Higher expression of uPA in invasive ductal carcinoma of the breast closely correlates with advanced disease stage and axillary lymph nodes involvement which predict a poorer prognosis, however, further follow-up study is needed.
出处
《外科理论与实践》
2005年第3期252-254,共3页
Journal of Surgery Concepts & Practice
关键词
乳腺肿瘤
预后
纤溶酶原激活剂
尿激酶型
肿瘤转移
Invasive ductal carcinoma
Prognostic factor
Axillary lymph nodes
Urokinase-type plasminogen activator
